The GLP-1 receptor agonist tablet was approved on 11 June 2026 by the Medicines and Healthcare products Regulatory Agency (MHRA)
An at-a-glance look at considerations for GLP-1 timing Still not sure which is the best fit for you
Findings from animal studies suggest that GLP-1R activation may promote anti-arteriosclerotic mechanisms inducing plaque stabilisation and preventing plaque progression (29, 30, 31, 32, 33)
While Ozempic contains the active GLP-1 ingredient semaglutide, not all GLP-1 drugs are Ozempic
This may include pacing your meals, avoiding rich foods during the first few weeks, increasing hydration, or modifying dosing schedules based on how your body responds
Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis